Clinical Trial Update: Toradol to Reduce Ureteroscopic Symptoms Trial [Phase 2]

View source ↗

Summary

Phase 2 trial investigating Toradol (ketorolac) to reduce ureteroscopic-related symptoms has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Disease
• Pain Postoperative
• Urinary Stones

Drugs mentioned

• Toradol (ketorolac tromethamine)

Snippet

Sponsor: Yale University | Conditions: Urinary Lithiasis, Kidney Diseases | Phase 2 | Status: COMPLETED | Results posted: 2021-11-02